Rolf P G van Heeswijk

Summary

Affiliation: University of Ottawa
Country: Canada

Publications

  1. ncbi request reprint Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience
    R P van Heeswijk
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    Antivir Ther 6:201-29. 2001
  2. ncbi request reprint Critical issues in therapeutic drug monitoring of antiretroviral drugs
    Rolf P G van Heeswijk
    International Antiviral Therapy Evaluation Center, Academic Medical Center, Amsterdam, The Netherlands
    Ther Drug Monit 24:323-31. 2002
  3. ncbi request reprint The pharmacokinetics of nelfinavir in HIV-1-infected children
    Rolf P G van Heeswijk
    Dept of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    Ther Drug Monit 24:487-91. 2002
  4. ncbi request reprint Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics
    Rolf P G van Heeswijk
    Clinical Investigation Unit, Division of Infectious Diseases, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada
    Expert Rev Anti Infect Ther 1:75-81. 2003
  5. pmc Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy
    Rieneke M E van Praag
    National AIDS Therapy Evaluation Center NATEC, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, University of Amsterdam, Amsterdam, The Netherlands
    Antimicrob Agents Chemother 46:896-9. 2002
  6. ncbi request reprint The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum
    Rolf P G van Heeswijk
    Division of Incectious Diseases and Department of Pharmacy, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada
    Clin Pharmacol Ther 76:588-97. 2004
  7. pmc Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor
    Joel G R Weaver
    Division of General Surgery, University of Ottawa, Ottawa, Ontario, Canada
    J Clin Invest 115:1828-38. 2005
  8. ncbi request reprint Comparative efflux of saquinavir, ritonavir and lopinavir from primary human cells
    Bilge Diker
    Public Health Agency of Canada, 200 Tunney s Pasture Driveway, Ottawa, Ontario, Canada
    Drug Metab Lett 4:241-5. 2010
  9. ncbi request reprint Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates
    Chokechai Rongkavilit
    HIV Netherlands Australia Thailand Research Collaboration HIV NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Acquir Immune Defic Syndr 29:455-63. 2002
  10. pmc Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study
    Rolf P G van Heeswijk
    Br J Clin Pharmacol 53:211-2. 2002

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience
    R P van Heeswijk
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    Antivir Ther 6:201-29. 2001
    ..This review covers combinations of saquinavir, indinavir, nelfinavir, amprenavir and lopinavir with different doses of ritonavir, as well as the combinations of saquinavir and indinavir with nelfinavir...
  2. ncbi request reprint Critical issues in therapeutic drug monitoring of antiretroviral drugs
    Rolf P G van Heeswijk
    International Antiviral Therapy Evaluation Center, Academic Medical Center, Amsterdam, The Netherlands
    Ther Drug Monit 24:323-31. 2002
    ..This review summarizes the basis for TDM of antiretroviral drugs and discusses the problems and prospects of this potential tool in the care for HIV-1-infected individuals...
  3. ncbi request reprint The pharmacokinetics of nelfinavir in HIV-1-infected children
    Rolf P G van Heeswijk
    Dept of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    Ther Drug Monit 24:487-91. 2002
    ..However, due to a large interpatient variability in the exposure, individual dosage adjustments based on plasma concentrations may be necessary for both dosing regimens to ensure optimal treatment...
  4. ncbi request reprint Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics
    Rolf P G van Heeswijk
    Clinical Investigation Unit, Division of Infectious Diseases, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada
    Expert Rev Anti Infect Ther 1:75-81. 2003
    ..This paper reviews the current literature on therapeutic drug monitoring and the inhibitory quotient in the management of HIV infection and speculates on the future role of pharmacogenomics in this therapeutic area...
  5. pmc Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy
    Rieneke M E van Praag
    National AIDS Therapy Evaluation Center NATEC, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, University of Amsterdam, Amsterdam, The Netherlands
    Antimicrob Agents Chemother 46:896-9. 2002
    ..While studies suggest that saquinavir concentrations decrease over time, we show that concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid are stable during 2 years of therapy...
  6. ncbi request reprint The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum
    Rolf P G van Heeswijk
    Division of Incectious Diseases and Department of Pharmacy, The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada
    Clin Pharmacol Ther 76:588-97. 2004
    ..The objective of this study was to explore the pharmacokinetics of nelfinavir and its active metabolite hydroxy-t-butylamidenelfinavir (M8) during pregnancy and post partum...
  7. pmc Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor
    Joel G R Weaver
    Division of General Surgery, University of Ottawa, Ottawa, Ontario, Canada
    J Clin Invest 115:1828-38. 2005
    ....
  8. ncbi request reprint Comparative efflux of saquinavir, ritonavir and lopinavir from primary human cells
    Bilge Diker
    Public Health Agency of Canada, 200 Tunney s Pasture Driveway, Ottawa, Ontario, Canada
    Drug Metab Lett 4:241-5. 2010
    ..All factors that may limit optimal estimation of cell-associated drug concentrations must be considered so that intracellular concentrations of drug can be accurately estimated...
  9. ncbi request reprint Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates
    Chokechai Rongkavilit
    HIV Netherlands Australia Thailand Research Collaboration HIV NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Acquir Immune Defic Syndr 29:455-63. 2002
    ..The highly variable systemic exposure observed in the study indicates that therapeutic drug monitoring seems warranted to ensure adequate NFV dosing in this population...
  10. pmc Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study
    Rolf P G van Heeswijk
    Br J Clin Pharmacol 53:211-2. 2002
  11. ncbi request reprint Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/r combination therapy in antiretroviral-experienced patients
    Tony Antoniou
    St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Ther Drug Monit 27:779-81. 2005
    ..No patient discontinued the regimen because of indinavir-related urologic or retinoid-type adverse effects. Further study of the regimen with larger cohorts of patients is necessary...
  12. ncbi request reprint Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects
    Mark A Boyd
    The HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    J Acquir Immune Defic Syndr 34:134-9. 2003
    ....
  13. ncbi request reprint Time-dependent interaction between lopinavir/ritonavir and fexofenadine
    Rolf P G van Heeswijk
    Ottawa Hospital, Divisio of Infectious Diseaeses, Canada
    J Clin Pharmacol 46:758-67. 2006
    ..Time-dependent inhibition of P-glycoprotein by lopinavir/ritonavir should be considered when P-glycoprotein substrates are coadministered...